Patents by Inventor Jian-Dong Li

Jian-Dong Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11003374
    Abstract: Embodiments of the present disclosure relate to methods, devices and computer program products for managing a redundant array of independent disks (RAID). The method comprises: in response to a number of a plurality of disks occupied by the RAID exceeding a first threshold, determining a first number of disk pairs to be disassociated among the plurality of disks, the first number of disk pairs at least comprising a first disk and a second disk associated with each other, and a first extent in the first disk and a second extent in the second disk being included in a same RAID extent of the RAID. The method further comprises determining a third disk for migrating at least one of the first extent and the second extent among the plurality of disks. Besides, the method further comprises migrating the at least one extent to the third disk to disassociate the first disk and the second disk so that a second number of disk pairs associated with each other among the plurality of disks is below a second threshold.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: May 11, 2021
    Assignee: EMC IP Holding Company LLC
    Inventors: Geng Han, Jian Gao, Liam Xiongcheng Li, Hongpo Gao, Jibing Dong
  • Patent number: 9951335
    Abstract: The present invention is based, in part, on our studies of molecular pathways that include the deubiquitinase CYLD. Accordingly, the present invention features, inter alia, nucleic acid constructs that express CYLD or a biologically active variant thereof (e.g., a variant including the catalytic domain), nucleic acids that inhibit the expression of a negative regulator of CYLD (e.g., PDE4B or LNK2), nucleic acids that modulate the expression of downstream CYLD targets (e.g., Akt, by inhibiting or promoting the expression of the downstream target), compositions including one or more of these types of constructs (e.g., pharmaceutical compositions), kits including one or more of the compositions described herein and instructions for use, screening methods to identify therapeutic agents {e.g., anti-inflammatory agents) that upregulate CYLD, downregulate a negative regulatory of CYLD, or modulate (e.g., inhibit) a downstream CYLD target (e.g.
    Type: Grant
    Filed: April 9, 2013
    Date of Patent: April 24, 2018
    Assignee: Georgia State University Research Foundation, Inc.
    Inventor: Jian-Dong Li
  • Publication number: 20180042904
    Abstract: The present invention features, inter alia, pharmaceutical compositions and their use in the preparation of a medicament (e.g., a medicament for inflammation, such as an inflammatory lung disease) or in a therapeutic regimen. The compositions can include at least two active agents: a first agent that inhibits PDE4 (e.g., roflumilast) and a second active agent that inhibits the expression or activity of one or more PDE4B variants (e.g., PDE4B2). The compositions and methods will attenuate an unwanted up-regulation of a PDE4B (e.g., PDE4B2) and may thereby improve treatment with the first agent (e.g., roflumilast). For example, the second agent may improve the efficacy of the first agent, decrease the effective dose of the first agent, ameliorate the tolerance to the first agent that would otherwise develop (e.g., in patients with COPD exacerbation), reduce unwanted side effects caused by the first agent, or otherwise improve treatment regimes including a PDE4 inhibitor.
    Type: Application
    Filed: March 21, 2016
    Publication date: February 15, 2018
    Inventor: Jian-Dong LI
  • Patent number: 9682070
    Abstract: Pharmaceutical compositions and methods for treating or preventing an inflammatory condition in a patient are disclosed. The pharmaceutical compositions and methods include the use of vincamine or a vincamine derivative, either alone or in combination with one or more additional therapeutic agents, including a steroid (preferably a corticosteroid), an angiotensin II receptor (type 1) antagonist, an angiotensin-converting enzyme (ACE) inhibitor, and a non-steroidal anti-inflammatory drug.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: June 20, 2017
    Assignee: University of Rochester
    Inventors: Chen Yan, Jian-Dong Li, Bradford Berk, Kye-Im Jeon, Xiangbin Xu
  • Publication number: 20160256444
    Abstract: Pharmaceutical compositions and methods for treating or preventing an inflammatory condition in a patient are disclosed. The pharmaceutical compositions and methods include the use of vincamine or a vincamine derivative, either alone or in combination with one or more additional therapeutic agents, including a steroid (preferably a corticosteroid), an angiotensin II receptor (type 1) antagonist, an angiotensin-converting enzyme (ACE) inhibitor, and a non-steroidal anti-inflammatory drug.
    Type: Application
    Filed: December 15, 2015
    Publication date: September 8, 2016
    Inventors: Chen Yan, Jian-Dong Li, Bradford Berk, Kye-Im Jeon, Xiangbin Xu
  • Publication number: 20160038590
    Abstract: The present invention features compositions and methods for targeted delivery of a therapeutic or imaging agent to a site accessible through the nose or mouth that may be difficult to effectively and efficiently treat otherwise (e.g., the middle ear, sinuses, or lung). The therapeutic or imaging agent is deposited onto a magnetic nanoparticle that is drawn through a passage or tissue that leads away from the nose or mouth by a magnetic field applied over the targeted site (e.g., by magnets within the ear canal or surrounding the ear).
    Type: Application
    Filed: March 15, 2014
    Publication date: February 11, 2016
    Inventor: Jian-Dong Li
  • Patent number: 9241932
    Abstract: Pharmaceutical compositions and methods for treating or preventing an inflammatory condition in a patient are disclosed. The pharmaceutical compositions and methods include the use of vincamine or a vincamine derivative, either alone or in combination with one or more additional therapeutic agents, including a steroid (preferably a corticosteroid), an angiotensin II receptor (type 1) antagonist, an angiotensin-converting enzyme (ACE) inhibitor, and a non-steroidal anti-inflammatory drug.
    Type: Grant
    Filed: February 26, 2014
    Date of Patent: January 26, 2016
    Assignee: UNIVERSITY OF ROCHESTER
    Inventors: Chen Yan, Jian-Dong Li, Bradford Berk, Kye-Im Jeon, Xiangbin Xu
  • Publication number: 20150065561
    Abstract: The present invention is based, in part, on our studies of molecular pathways that include the deubiquitinase CYLD. Accordingly, the present invention features, inter alia, nucleic acid constructs that express CYLD or a biologically active variant thereof (e.g., a variant including the catalytic domain), nucleic acids that inhibit the expression of a negative regulator of CYLD (e.g., PDE4B or LNK2), nucleic acids that modulate the expression of downstream CYLD targets (e.g., Akt, by inhibiting or promoting the expression of the downstream target), compositions including one or more of these types of constructs (e.g., pharmaceutical compositions), kits including one or more of the compositions described herein and instructions for use, screening methods to identify therapeutic agents {e.g., anti-inflammatory agents) that upregulate CYLD, downregulate a negative regulatory of CYLD, or modulate (e.g., inhibit) a downstream CYLD target (e.g.
    Type: Application
    Filed: April 9, 2013
    Publication date: March 5, 2015
    Applicant: Georgia State University Research Foundation, Inc.
    Inventor: Jian-Dong Li
  • Publication number: 20140296273
    Abstract: Pharmaceutical compositions and methods for treating or preventing an inflammatory condition in a patient are disclosed. The pharmaceutical compositions and methods include the use of vincamine or a vincamine derivative, either alone or in combination with one or more additional therapeutic agents, including a steroid (preferably a corticosteroid), an angiotensin II receptor (type 1) antagonist, an angiotensin-converting enzyme (ACE) inhibitor, and a non-steroidal anti-inflammatory drug.
    Type: Application
    Filed: February 26, 2014
    Publication date: October 2, 2014
    Inventors: Chen Yan, Jian-Dong Li, Bradford Berk, Kye-Im Jeon, Xiangbin Xu
  • Patent number: 8716237
    Abstract: The present invention relates to a method for treatment or prevention of a hemorrhagic condition in a patient by administering plasminogen activator inhibitor-1 (“PAI-1”) and/or an inhibitor of deubiquitinating enzyme CYLD (“CYLD”) to a patient. Pharmaceutical compositions that include one or both of PAI-1 and an inhibitor of CYLD are also disclosed.
    Type: Grant
    Filed: July 22, 2008
    Date of Patent: May 6, 2014
    Assignee: University of Rochester
    Inventors: Jian-Dong Li, Jae Hyang Lim
  • Publication number: 20110190373
    Abstract: The invention relates to methods of treating or preventing pathological cardiac remodeling and/or preventing heart failure. These methods include the administration of a PDE1 inhibitor to a patient under conditions effective to treat or prevent pathological cardiac remodeling, and therefore heart failure that occurs as a result of such remodeling. Pharmaceutical compositions and delivery vehicles that can be used in the methods of the present invention are also disclosed herein.
    Type: Application
    Filed: May 5, 2009
    Publication date: August 4, 2011
    Applicant: UNIVERSITY OF ROCHESTER
    Inventors: Chen Yan, Jian-Dong Li
  • Patent number: 7985729
    Abstract: The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
    Type: Grant
    Filed: April 21, 2010
    Date of Patent: July 26, 2011
    Assignee: House Research Institute
    Inventors: David J. Lim, Haa-Yung Lee, Paul Webster, Ali Andalibi, Jian-Dong Li, Tomas Ganz, Kiweon Cha
  • Publication number: 20100221340
    Abstract: Pharmaceutical compositions and methods for treating or preventing an inflammatory condition in a patient are disclosed. The pharmaceutical compositions and methods include the use of vincamine or a vincamine derivative, either alone or in combination with one or more additional therapeutic agents, including a steroid (preferably a corticosteroid), an angiotensin II receptor (type 1) antagonist, an angiotensin-converting enzyme (ACE) inhibitor, and a non-steroidal anti-inflammatory drug.
    Type: Application
    Filed: September 16, 2008
    Publication date: September 2, 2010
    Applicant: UNIVERSITY OF ROCHESTER
    Inventors: Chen Yan, Jian-Dong Li, Bradford Berk, Kye-im Jeon, Xiangbin Xu
  • Publication number: 20100215668
    Abstract: The present invention relates to a method for treatment or prevention of a hemorrhagic condition in a patient by administering plasminogen activator inhibitor-1 (“PAI-1”) and/or an inhibitor of deubiquitinating enzyme CYLD (“CYLD”) to a patient. Pharmaceutical compositions that include one or both of PAI-1 and an inhibitor of CYLD are also disclosed.
    Type: Application
    Filed: July 22, 2008
    Publication date: August 26, 2010
    Applicant: UNIVERSITY OF ROCHESTER
    Inventors: Jian-Dong Li, Jae Hyang Lim
  • Publication number: 20100204447
    Abstract: The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
    Type: Application
    Filed: April 21, 2010
    Publication date: August 12, 2010
    Applicant: HOUSE EAR INSTITUTE
    Inventors: DAVID J. LIM, HAA-YUNG LEE, PAUL WEBSTER, ALI ANDALIBI, JIAN-DONG LI, TOMAS GANZ, KIWEON CHA
  • Publication number: 20090023893
    Abstract: The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
    Type: Application
    Filed: July 16, 2008
    Publication date: January 22, 2009
    Applicant: House Ear Institute
    Inventors: David J. Lim, Haa-Yung Lee, Paul Webster, Ali Andalibi, Jian-Dong Li, Tomas Ganz, Kiweon Cha
  • Patent number: 7338936
    Abstract: The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
    Type: Grant
    Filed: October 22, 2004
    Date of Patent: March 4, 2008
    Assignee: House Ear Institute
    Inventors: David J. Lim, Haa-Yung Lee, Paul Webster, Ali Andalibi, Jian-Dong Li, Tomas Ganz, Kiweon Cha
  • Publication number: 20070207963
    Abstract: The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
    Type: Application
    Filed: May 18, 2007
    Publication date: September 6, 2007
    Applicant: HOUSE EAR INSTITUTE
    Inventors: David Lim, Haa-Yung Lee, Paul Webster, Ali Andalibi, Jian-Dong Li, Tomas Ganz, Kiweon Cha
  • Patent number: 7060674
    Abstract: Disclosed herein is a composition and a method for the treatment of otitis media and paranasal sinusitis using human defensins, lysozyme and/or lactoferrin as a new class of non-antibiotic antimicrobials. From studies of otitis media and paranasal sinusitis, it was observed that certain innate immune modulators were important in the bodies response to the infection. Therefore, these innate immune modulators, lysozyme, lactoferrin, and defensins were tested for use as a non-antibiotic treatment for infection, particularly infections such as otitis media and sinusitis.
    Type: Grant
    Filed: April 6, 2004
    Date of Patent: June 13, 2006
    Assignee: House Ear Institute
    Inventors: David J. Lim, Haa-Yung Lee, Paul Webster, Ali Andalibi, Jian-Dong Li, Tomas Ganz
  • Publication number: 20060034820
    Abstract: The pharmaceutical composition and a method of treatment of infectious diseases, such as otitis media, paranasal sinusitis, labyrinthitis and meningitis are described. The composition comprises EP2E or homologues thereof.
    Type: Application
    Filed: October 22, 2004
    Publication date: February 16, 2006
    Inventors: David Lim, Haa-Yung Lee, Paul Webster, Ali Andalibi, Jian-Dong Li, Tomas Ganz, Kiweon Cha